197 related articles for article (PubMed ID: 32720048)
1. Contralateral Risk-Reducing Mastectomy in Breast Cancer Patients Who Undergo Multigene Panel Testing.
Murphy BL; Yi M; Arun BK; Gutierrez Barrera AM; Bedrosian I
Ann Surg Oncol; 2020 Nov; 27(12):4613-4621. PubMed ID: 32720048
[TBL] [Abstract][Full Text] [Related]
2. Contralateral prophylactic mastectomy rate and predictive factors among patients with breast cancer who underwent multigene panel testing for hereditary cancer.
Elsayegh N; Webster RD; Gutierrez Barrera AM; Lin H; Kuerer HM; Litton JK; Bedrosian I; Arun BK
Cancer Med; 2018 Jun; 7(6):2718-2726. PubMed ID: 29733510
[TBL] [Abstract][Full Text] [Related]
3. Impact of Multigene Panel Testing on Surgical Decision Making in Breast Cancer Patients.
Pederson HJ; Gopalakrishnan D; Noss R; Yanda C; Eng C; Grobmyer SR
J Am Coll Surg; 2018 Apr; 226(4):560-565. PubMed ID: 29360614
[TBL] [Abstract][Full Text] [Related]
4. The Angelina Jolie effect: Contralateral risk-reducing mastectomy trends in patients at increased risk of breast cancer.
Basu NN; Hodson J; Chatterjee S; Gandhi A; Wisely J; Harvey J; Highton L; Murphy J; Barnes N; Johnson R; Barr L; Kirwan CC; Howell S; Baildam AD; Howell A; Evans DG
Sci Rep; 2021 Feb; 11(1):2847. PubMed ID: 33531640
[TBL] [Abstract][Full Text] [Related]
5. Timely cancer genetic counseling and testing for young women with breast cancer: impact on surgical decision-making for contralateral risk-reducing mastectomy.
Dettwyler SA; Thull DL; McAuliffe PF; Steiman JG; Johnson RR; Diego EJ; Mai PL
Breast Cancer Res Treat; 2022 Jul; 194(2):393-401. PubMed ID: 35596825
[TBL] [Abstract][Full Text] [Related]
6. Risk-reducing mastectomy for the prevention of primary breast cancer.
Carbine NE; Lostumbo L; Wallace J; Ko H
Cochrane Database Syst Rev; 2018 Apr; 4(4):CD002748. PubMed ID: 29620792
[TBL] [Abstract][Full Text] [Related]
7. Contralateral risk-reducing mastectomy in young breast cancer patients with and without genetic cancer risk assessment.
Mai PL; Lagos VI; Palomares MR; Weitzel JN
Ann Surg Oncol; 2008 Dec; 15(12):3415-21. PubMed ID: 18836779
[TBL] [Abstract][Full Text] [Related]
8. Feasibility study of contralateral risk-reducing mastectomy with breast reconstruction for breast cancer patients with BRCA mutations in Japan.
Yoshimura A; Okumura S; Sawaki M; Hattori M; Ishiguro J; Adachi Y; Kotani H; Gondo N; Kataoka A; Iwase M; Onishi S; Sugino K; Terada M; Horisawa N; Mori M; Takaiso N; Hyodo I; Iwata H
Breast Cancer; 2018 Sep; 25(5):539-546. PubMed ID: 29520501
[TBL] [Abstract][Full Text] [Related]
9. Contralateral risk-reducing mastectomy in BRCA1 and BRCA2 mutation carriers and other high-risk women in the Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab).
Kiely BE; Jenkins MA; McKinley JM; Friedlander ML; Weideman P; Milne RL; McLachlan SA; Hopper JL; Phillips KA
Breast Cancer Res Treat; 2010 Apr; 120(3):715-23. PubMed ID: 19669874
[TBL] [Abstract][Full Text] [Related]
10. Improved overall survival after contralateral risk-reducing mastectomy in BRCA1/2 mutation carriers with a history of unilateral breast cancer: a prospective analysis.
Heemskerk-Gerritsen BA; Rookus MA; Aalfs CM; Ausems MG; Collée JM; Jansen L; Kets CM; Keymeulen KB; Koppert LB; Meijers-Heijboer HE; Mooij TM; Tollenaar RA; Vasen HF; ; Hooning MJ; Seynaeve C
Int J Cancer; 2015 Feb; 136(3):668-77. PubMed ID: 24947112
[TBL] [Abstract][Full Text] [Related]
11. Multigene Panel Testing Detects Equal Rates of Pathogenic BRCA1/2 Mutations and has a Higher Diagnostic Yield Compared to Limited BRCA1/2 Analysis Alone in Patients at Risk for Hereditary Breast Cancer.
Kapoor NS; Curcio LD; Blakemore CA; Bremner AK; McFarland RE; West JG; Banks KC
Ann Surg Oncol; 2015 Oct; 22(10):3282-8. PubMed ID: 26219241
[TBL] [Abstract][Full Text] [Related]
12. Clinical Management of Patients at Risk for Hereditary Breast Cancer with Variants of Uncertain Significance in the Era of Multigene Panel Testing.
Chang J; Seng S; Yoo J; Equivel P; Lum SS
Ann Surg Oncol; 2019 Oct; 26(10):3389-3396. PubMed ID: 31342386
[TBL] [Abstract][Full Text] [Related]
13. Contralateral mastectomy improves survival in women with BRCA1/2-associated breast cancer.
Evans DG; Ingham SL; Baildam A; Ross GL; Lalloo F; Buchan I; Howell A
Breast Cancer Res Treat; 2013 Jul; 140(1):135-42. PubMed ID: 23784379
[TBL] [Abstract][Full Text] [Related]
14. Association Between Genetic Testing for Hereditary Breast Cancer and Contralateral Prophylactic Mastectomy Among Multiethnic Women Diagnosed With Early-Stage Breast Cancer.
Ro V; McGuinness JE; Guo B; Trivedi MS; Jones T; Chung WK; Rao R; Levinson E; Koval C; Russo D; Chilton I; Kukafka R; Crew KD
JCO Oncol Pract; 2022 Apr; 18(4):e472-e483. PubMed ID: 34705516
[TBL] [Abstract][Full Text] [Related]
15. Influence of germline test results on surgical decision making in women with invasive breast cancer.
Vargason AB; Turner CE; Shriver CD; Ellsworth RE
Cancer Genet; 2022 Aug; 266-267():81-85. PubMed ID: 35868102
[TBL] [Abstract][Full Text] [Related]
16. Oncologic Safety of Prophylactic Nipple-Sparing Mastectomy in a Population With BRCA Mutations: A Multi-institutional Study.
Jakub JW; Peled AW; Gray RJ; Greenup RA; Kiluk JV; Sacchini V; McLaughlin SA; Tchou JC; Vierkant RA; Degnim AC; Willey S
JAMA Surg; 2018 Feb; 153(2):123-129. PubMed ID: 28903167
[TBL] [Abstract][Full Text] [Related]
17. Assessment of the effect of the American Society of Breast Surgery guidelines on contralateral prophylactic mastectomy rates for unilateral breast cancer.
Steadman JA; Hoskin TL; Klassen C; Boughey JC; Degnim AC; Piltin MA; Mrdutt MM; Johnson JE; Hieken TJ
Surgery; 2024 Mar; 175(3):677-686. PubMed ID: 37863697
[TBL] [Abstract][Full Text] [Related]
18. Contralateral risk-reducing local therapy in breast cancer patients with BRCA1/2 mutations: systemic review and meta-analysis.
Jia Z; Li J; Zhang Y; Wang X; Xing J; Xing Z; Huang X; Liu G; Zhang M; Feng K; Wu J; Wang W; Wang J; Liu J; Wang X
Cancer Cell Int; 2021 Sep; 21(1):512. PubMed ID: 34563200
[TBL] [Abstract][Full Text] [Related]
19. Risk management decisions in women with BRCA1 and BRCA2 mutations.
Morgan R; Brown A; Hamman KJ; Sampson J; Naik A; Massimino K
Am J Surg; 2018 May; 215(5):899-903. PubMed ID: 29499861
[TBL] [Abstract][Full Text] [Related]
20. Impact that Timing of Genetic Mutation Diagnosis has on Surgical Decision Making and Outcome for BRCA1/BRCA2 Mutation Carriers with Breast Cancer.
Chiba A; Hoskin TL; Hallberg EJ; Cogswell JA; Heins CN; Couch FJ; Boughey JC
Ann Surg Oncol; 2016 Oct; 23(10):3232-8. PubMed ID: 27338744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
